Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus will present data on CPI-006 in an oral presentation and two poster sessions:
| Oral Presentation: | |
| Abstract O40: | Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers. |
| Presenter: | Jason J. Luke, M.D., FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center |
| Session Title: | Session 204: Immune Checkpoints: Newer Targets and Update on Combinations |
| Date and Time: | Friday, November 8, 2019 from 3:45 pm – 4:00 pm ET |
| Poster Presentations: | |
| Poster P125: | Adenosine and AMP gene expression profiles predict response to adenosine pathway therapies and indicate a need for dual blockade of CD73 and A2AR with CD73 inhibitors. |
| Presenter: | Stephen Willingham, PhD, Corvus Senior Scientist |
| Poster Session: | Biomarkers, Immune Monitoring, and Novel Technologies |
| Date and Time: | Friday, November 8, 2019 from 7:00 am – 8:00 pm ET |
| Location: | Poster Hall: Prince George AB / Gaylord National Hotel & Convention Center |
| Poster P434: | A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers. |
| Presenter: | Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer |
| Poster Session: | Clinical Trial in Progress |
| Date and Time: | Saturday, November 9, 2019 from 7:00 am – 8:30 pm ET |
| Location: | Poster Hall: Prince George AB / Gaylord National Hotel & Convention Center |
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and with pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Chief Financial Officer
650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT:
W2O pure
+1 213-262-9390
sseapy@purecommunications.com
Source: Corvus Pharmaceuticals, Inc.
